Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786391 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3BTKCYP11B1 | |
| SCHEMBL1786390 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3BTKCYP11B1 | |
| SCHEMBL1785175 | 0.90 | CHRM2 (0.39) | CHRM2CHRM1CHRM3CYP11B1CYP11B2 | |
| SCHEMBL12607077 | 0.90 | CHRM2 (0.39) | CHRM2CHRM1CHRM3CYP11B1CYP11B2 | |
| SCHEMBL1786907 | 0.90 | CHRM2 (0.39) | CHRM2CHRM1CHRM3CYP11B1CYP11B2 | |
| SCHEMBL20722022 | 0.87 | BTK (0.36) | CHRM2CHRM1CHRM3BTKCYP11B1 | |
| SCHEMBL20722075 | 0.85 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CYP11B1CYP11B2 | |
| SCHEMBL20722074 | 0.85 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CYP11B1CYP11B2 | |
| SCHEMBL22616385 | 0.85 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CYP11B1CYP11B2 | |
| SCHEMBL27436810 | 0.83 | EPHX1 (0.37) | CHRM2CHRM1CHRM3BTKCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | CHRM2 4365/4885CHRM1 4277/4885CHRM3 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.